TargetBeta
PRRT2
proline rich transmembrane protein 2 · also FLJ25513, DKFZp547J199, IFITMD1, FICCA · Dispanins
2 programs in company-led studies act on PRRT2, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| darovasertibrule | IDEAYA Biosciences | phase 3 | 65 running | – | NCIt |
| PKC-beta Inhibitor MS-553rule | MingSight Pharmaceuticals | phase 2 | 62 running | – | NCIt |
Conditions their studies are in
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 program
- Lymphoma, Large B-Cell, Diffuse, 1 program
- Macular Edema, 1 program
- Uveal Melanoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jan 15, 2027darovasertib · IDEAYA Biosciences · phase 3 · NCT05987332
- Sep 2028PKC-beta Inhibitor MS-553 · MingSight Pharmaceuticals · phase 2 · NCT06979076
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.